Berenberg just raised their price target on BioNTech shares to $155. The investment bank's upgraded outlook signals growing confidence in the biotech company's trajectory. Analysts are clearly seeing something promising in BioNTech's fundamentals—whether it's their pipeline development, revenue projections, or market positioning. This kind of target revision from a major European bank usually catches attention from institutional investors. Worth noting that biotech stocks have been volatile lately, so a bullish call like this stands out. The $155 mark represents a significant upside from current levels, suggesting Berenberg expects strong performance ahead.